deltatrials
Completed PHASE2 NCT00020930

Cetuximab in Treating Patients With Stage IV Colorectal Cancer

Phase II Study of an Anti-Epidermal Growth Factor Receptor (EGFR) Antibody, Cetuximab, in Patients With Irinotecan-Refractory, Stage IV Colorectal Carcinoma

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Colorectal Cancer
Interventions cetuximab
Updated 5 times since 2017 Last updated: Dec 3, 2009 Started: Mar 31, 2001 Primary completion: Aug 31, 2002

Listed as NCT00020930, this PHASE2 trial focuses on Colorectal Cancer and remains completed. Sponsored by Memorial Sloan Kettering Cancer Center, it has been updated 5 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Mar 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Memorial Sloan Kettering Cancer Center
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New York, United States